Electronic Alert System for Improving Thromboprophylaxis in Hospitalized Medical Patients

Electronic Alert System Combined With a Risk Score Calculation Tool for Improving Appropriate Thromboprophylaxis in Hospitalized Medical Patients: a Randomized Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03124017

Enrollment

1756

Registered

2017-04-21

Start date

2015-03-31

Completion date

2016-06-30

Last updated

2017-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Thromboembolism

Brief summary

The investigators aim to investigate whether a computer-based alert system in the electronic patient chart and order entry system using the Geneva Risk Score as clinical decision support tool to estimate the risk of venous thromboembolism improves the rate of appropriate thromboprophylaxis among hospitalized medical patients.

Detailed description

The use of thromboprophylaxis among acutely ill hospitalized medical patients remains inconsistent. The present study aims to improve the use of appropriate thromboprophylaxis by implementing a computer-based alert system combined with a Geneva Risk Score calculation tool in the electronic patient chart and order entry system. Consecutive acutely ill medical patients without indication for therapeutic anticoagulation or ongoing therapeutic anticoagulant treatment admitted to the medical wards of the University Hospital Bern, Switzerland, will be randomized in a 1:1 fashion to the alert group in which an alert and the Geneva Risk Score calculation tool will be issued in the electronic patient chart or to the control group in which no alert will be issued. The primary endpoint is the rate of appropriate thromboprophylaxis during hospital stay.

Interventions

OTHERElectronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Acutely ill medical patients admitted to medical wards

Exclusion criteria

* Indication for therapeutic anticoagulation or ongoing therapeutic anticoagulant treatment

Design outcomes

Primary

Measure	Time frame
Rate of appropriate thromboprophylaxis	During hospital stay (expected average duration of 1 week)

Secondary

Measure	Time frame
Use of the Geneva Risk Score calculation tool by the physician in charge	During hospital stay (expected average duration of 1 week)
Rate of correct calculation of the Geneva Risk Score through the calculation tool by the physician in charge	During hospital stay (expected average duration of 1 week)

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026